RENESE-R Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Renese-r, and when can generic versions of Renese-r launch?
Renese-r is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in RENESE-R is polythiazide; reserpine. There is one drug master file entry for this compound. Additional details are available on the polythiazide; reserpine profile page.
Summary for RENESE-R
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RENESE-R at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for RENESE-R
US Patents and Regulatory Information for RENESE-R
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | RENESE-R | polythiazide; reserpine | TABLET;ORAL | 013636-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |